Brokerages Set argenx SE (NASDAQ:ARGX) Price Target at $535.37

Shares of argenx SE (NASDAQ:ARGX) have earned an average recommendation of “Moderate Buy” from the twenty-one ratings firms that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $540.37.

ARGX has been the topic of a number of recent analyst reports. Piper Sandler lifted their price objective on argenx from $522.00 to $535.00 and gave the stock an “overweight” rating in a research report on Monday, June 24th. William Blair reissued a “market perform” rating on shares of argenx in a research report on Monday, June 17th. HC Wainwright raised their target price on shares of argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Morgan Stanley reduced their price target on shares of argenx from $515.00 to $510.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 28th. Finally, Wells Fargo & Company raised their price objective on shares of argenx from $543.00 to $547.00 and gave the stock an “overweight” rating in a report on Friday, July 26th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Lindbrook Capital LLC increased its holdings in argenx by 23.1% in the 1st quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock worth $78,000 after buying an additional 37 shares in the last quarter. Wahed Invest LLC grew its stake in shares of argenx by 9.6% in the fourth quarter. Wahed Invest LLC now owns 457 shares of the company’s stock worth $174,000 after acquiring an additional 40 shares during the period. GAMMA Investing LLC raised its holdings in shares of argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in argenx by 2.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,530 shares of the company’s stock valued at $582,000 after purchasing an additional 41 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its position in argenx by 3.1% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 1,428 shares of the company’s stock worth $543,000 after purchasing an additional 43 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of argenx stock opened at $516.18 on Friday. The stock has a market capitalization of $30.87 billion, a P/E ratio of -91.20 and a beta of 0.64. argenx has a one year low of $327.73 and a one year high of $532.59. The business’s 50 day simple moving average is $424.48 and its two-hundred day simple moving average is $397.51.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. The firm had revenue of $489.43 million for the quarter, compared to analysts’ expectations of $436.66 million. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. During the same quarter in the previous year, the company earned ($1.69) earnings per share. Sell-side analysts expect that argenx will post -0.48 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.